Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials | Zendy

Hong-Xing Wu | Zendy; Keke Liu | Zendy; BoNing Li | Zendy; Sha Liu | Zendy; Jingchun Jin | Zendy

Open Access

Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials

Author(s) -

Hong-Xing Wu,

Keke Liu,

BoNing Li,

Sha Liu,

Jingchun Jin

Publication year - 2022

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-22-503

Subject(s) - medicine , valsartan , sacubitril, valsartan , blood pressure , sacubitril , meta analysis , randomized controlled trial , clinical trial

With the increase of hypertensive patients worldwide, the need for better antihypertensive drugs to achieve blood pressure standards and reduce complications is of great clinical significance. As an angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan has been widely used in the treatment of heart failure, but its efficacy and safety in the treatment of middle-aged and elderly hypertensive patients are still controversial. Therefore, we performed a meta-analysis to compare the efficacy and safety of sacubitril/valsartan and other antihypertensive drugs in the treatment of middle-aged and elderly patients with hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research